enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Nivolumab/relatlimab - Wikipedia

    en.wikipedia.org/wiki/Nivolumab/relatlimab

    Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab , a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab , a lymphocyte activation gene-3 (LAG-3) blocking antibody. [ 10 ]

  3. Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC

    www.aol.com/news/bristol-myers-opdivo-yervoy...

    Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.

  4. Bristol Myers' Opdivo-Yervoy combo meets main goal in liver ...

    www.aol.com/news/bristol-myers-opdivo-yervoy...

    Opdivo, which is one of the top sellers for Bristol Myers, brought in $9.01 billion in revenue in 2023, while Yervoy earned $2.24 billion in the same period. (Reporting by Puyaan Singh; Editing by ...

  5. Bristol Myers' Opdivo Combo Treatment Scores European ...

    www.aol.com/news/bristol-myers-opdivo-combo...

    The European Commission approved Bristol Myers Squibb & Co's (NYSE: BMY) fixed-dose combination of Opdualag (nivolumab and relatlimab) for melanoma patients aged 12 years and above. Melanoma is a ...

  6. Checkpoint inhibitor - Wikipedia

    en.wikipedia.org/wiki/Checkpoint_inhibitor

    [2] Currently approved checkpoint inhibitors target the molecules CTLA4, PD-1, and PD-L1. PD-1 is the transmembrane programmed cell death 1 protein (also called PDCD1 and CD279), which interacts with PD-L1 (PD-1 ligand 1, or CD274). PD-L1 on the cell surface binds to PD-1 on an immune cell surface, which inhibits immune cell activity.

  7. Nivolumab - Wikipedia

    en.wikipedia.org/wiki/Nivolumab

    Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...

  8. Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

    www.aol.com/news/bristol-myers-bmy-opdivo-yervoy...

    Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

  9. Nivolumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Nivolumab/hyaluronidase

    Nivolumab/hyaluronidase, sold under the brand name Opdivo Qvantig, is a fixed-dose combination anti-cancer medication used for the treatment of various forms of cancer. [ 1 ] [ 2 ] Nivolumab/hyaluronidase contains nivolumab , a programmed death receptor-1 (PD-1)-blocking monoclonal antibody ; and hyaluronidase , an endoglycosidase . [ 1 ]